The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMW 2021 | Optimal treatment sequencing for relapsed/refractory myeloma
Philippe Moreau, MD, Nantes University Hospital, Nantes, France, talks on optimizing the treatment sequence for patients with multiple myeloma. Prof. Moreau discusses the importance of considering lenalidomide-refractoriness after first relapse and the use of pomalidomide with bortezomib and dexamethasone (PomVd) or carfilzomib, and dexamethasone plus either daratumumab or isatuximab, for lenalidomide-refractory patients. For patients who remain lenalidomide-sensitive after first relapse, Prof. Moreau suggests daratumumab, lenalidomide and dexamethasone. For the second relapse, one strategy proposed is pomalidomide-dexamethasone or carfilzomib-dexamethasone with either daratumumab or isatuximab in conjunction with an anti-CD38 antibody. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
